Treatment Options for Pyoderma Gangrenosum

First-Line Treatment

Systemic corticosteroids are traditionally considered the primary treatment option with the therapeutic goal of rapid healing, as this can be a debilitating skin disorder 1, 2, 3
The European Crohn’s and Colitis Organisation recommends systemic corticosteroids as the first-line treatment for pyoderma gangrenosum, with the goal of achieving rapid healing 1, 2
For smaller lesions, topical calcineurin inhibitors (tacrolimus or pimecrolimus) can be used as alternatives or adjuncts to systemic therapy 1, 3, 4
Daily wound care should be performed in collaboration with a wound-care specialist 1

Adalimumab has demonstrated efficacy in multiple case series and should be considered as the alternative anti-TNF option when infliximab is unavailable 1, 2, 3, 4
The American Gastroenterological Association suggests adalimumab as a viable alternative to infliximab for the treatment of pyoderma gangrenosum 1, 2
Ciclosporin (cyclosporine) has been traditionally used for refractory cases, with established clinical experience 1, 2
Oral or intravenous tacrolimus can be reserved for cases not responding to other treatments 1, 2
Azathioprine may be used for patients with frequent relapses or resistant cases, particularly when there is concurrent inflammatory bowel disease 2

Closure of the stoma might lead to complete resolution of PG lesions in patients with peristomal disease, and should be considered as a definitive treatment option when medically feasible 1, 2, 4
Response rates are significantly better with short duration PG (<12 weeks), where treatment success exceeds 90% 1, 2, 3
For chronic cases (>3 months duration), response rates drop below 50%, making early aggressive treatment critical 1, 4

Never perform surgical debridement during active disease due to pathergy (trauma-induced lesion worsening at sites of injury), which occurs in 20-30% of cases 3, 4, 5
Rule out ecthyma gangrenosum (bacterial vasculitis) before initiating immunosuppression, as this requires antibiotics, not immunosuppression 3, 4
Screen for underlying conditions: 50-70% of PG cases have associated systemic diseases, particularly inflammatory bowel disease (especially ulcerative colitis), hematological malignancies, and rheumatologic disorders 5

Start with systemic corticosteroids as first-line therapy, adding topical calcineurin inhibitors for smaller lesions 1, 2, 3
If inadequate response to corticosteroids within 2-4 weeks, initiate adalimumab as the preferred alternative anti-TNF agent 1, 3, 4
For steroid-dependent or anti-TNF failures, consider traditional immunosuppressives: ciclosporin or tacrolimus (oral or IV) 1, 2
For peristomal PG, strongly consider stoma closure as definitive treatment if medically appropriate 1, 2, 4

Recurrence occurs in >25% of cases, often at the same anatomical location as the initial episode, requiring long-term surveillance even after successful treatment 1, 3, 5
Lesions typically heal within 4 weeks after successful treatment 4
The pathophysiology involves abnormal neutrophil function and impaired cellular immunity, with lesions often preceded by trauma (pathergy phenomenon) 1